LEO Pharma appoints Christophe Bourdon as new CEO
Ballerup, January 31, 2022 – LEO Pharma today announced the appointment of Christophe Bourdon as new Chief Executive Officer of the company, effective April 1, 2022. Christophe Bourdon joins from Orphazyme A/S where he has held the position as CEO since April 2021, following significant global leadership roles in both Amgen and Alexion.
LEO Pharma is taking significant steps to transform the company to become a competitive, global player in the growing dermatology market, successfully launch a global product portfolio and prepare the company for a public listing (IPO).
To lead this, the Board of Directors of LEO Pharma today announced the appointment of Christophe Bourdon as new CEO as of April 1, 2022.
“I am thrilled that Christophe Bourdon joins LEO Pharma as new CEO. Christophe Bourdon is an international and accomplished leader. I am confident that he is the right person to lead LEO Pharma’s transformation towards becoming a publicly listed leader in medical dermatology. The Board of Directors is looking forward to working closely with Christophe Bourdon and the Global Leadership Team on the next chapters of LEO Pharma’s growth journey,” said Chairman of the Board of Directors, Jesper Brandgaard.
Christophe Bourdon will join from a role as CEO of Orphazyme A/S. His previous roles include Senior Vice President, General Manager, U.S. Oncology Business, at US biotech Amgen Inc. where he also led commercialization planning of top-selling drugs on the global market. Prior to Amgen, Christophe Bourdon was Senior Vice President of Europe, Middle East, Africa, and Canada at Alexion as the company launched two breakthrough ultra-orphan drugs and negotiated payor access across UK, Germany, France, Italy, and Canada. Christophe Bourdon holds an MBA from IMD Business School (Switzerland) and a BA from ISG (France).
“I am excited to join LEO Pharma and bring my competences and experience into play as LEO Pharma goes through the next phases of its transformation. The company’s strong heritage appeals to me as well as the unique profile in medical dermatology. LEO Pharma has a huge potential for growth and for making a difference for people who need more treatment options for their skin conditions,” said Christophe Bourdon.
Tel: +45 3166 1567
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10.133 billion.
For more information about LEO Pharma, visit www.leo-pharma.com.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO PHARMA LAUNCHES AD DAYS AROUND THE WORLD CAMPAIGN TO RAISE AWARENESS OF THE IMPACT OF ATOPIC DERMATITIS ACROSS CULTURES3.10.2022 07:00:00 CEST | Press release
• In partnership with Global patient advocate Ashley Ann Lora, AD Days Around the World explores the impact of atopic dermatitis (AD) on the lives of individuals around the world living with this chronic and debilitating skin disease • The campaign features the emotional journey of four patient advocates from France, Italy, Germany and Spain and showcases the impact that AD has on people, regardless of culture or geography
LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis29.9.2022 07:00:00 CEST | Press release
LEO Pharma and DKSH have entered into an agreement to bring high-quality therapeutic products for dermatology and thrombosis to patients across Asia. This agreement both supports LEO Pharma’s strategy of building a simpler and more competitive organization and DKSH Business Unit Healthcare’s strategic focus of strengthening its regional footprint.
LEO Pharma receives positive CHMP opinion of Adtralza® (tralokinumab) for the treatment of adolescents with moderate-to-severe atopic dermatitis19.9.2022 07:30:00 CEST | Press release
• Positive CHMP opinion recommends extending use of Adtralza® (tralokinumab) to adolescents (12-17 years old) in the European Union (EU) • Recommendation supported by data from the Phase 3 ECZTRA 6 trial
LEO Pharma presents new Adtralza® safety data in moderate-to-severe atopic dermatitis at the 31st EADV Congress8.9.2022 14:15:00 CEST | Press release
• An interim safety analysis from ECZTEND, an open-label, 5-year extension trial, demonstrated consistent safety from the parent trials for up to 3.5 years of Adtralza® (tralokinumab) treatment in adult patients with moderate-to-severe atopic dermatitis.1 • Exposure-adjusted incidence rates of adverse events of special interest, including conjunctivitis, eczema herpeticum, and skin infections requiring systemic treatment, were generally lower than rates reported during the placebo-controlled period up to Week 16 and declined over time.1
LEO Pharma appoints Paul Navarre new member of its Board of Directors31.8.2022 08:00:00 CEST | Press release
Ballerup, Denmark, August 31, 2022 – LEO Pharma today announced the appointment of Paul Navarre as new member of its Board of Directors.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom